Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsNew and emerging HDAC inhibitors for cancer treatmentHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyPhase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Target engagement and drug residence time can be observed in living cells with BRET.Profiling deacetylase activities in cell lysates with peptide arrays and SAMDI mass spectrometry.Current evidence for histone deacetylase inhibitors in pancreatic cancer.Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells.Histone deacetylases and the immunological network: implications in cancer and inflammation.Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.Toxicological and metabolic considerations for histone deacetylase inhibitors.Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Selective in vivo metabolic cell-labeling-mediated cancer targeting.Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.New emerging therapies in the management of chronic lymphocytic leukemia.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease.Cellular analysis of the action of epigenetic drugs and probes.Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesPimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Total synthesis of (18S)- and (18R)-homolargazole by rhodium-catalyzed hydrocarboxylation.Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.
P2860
Q21198868-08CA80D5-BB93-46A8-A1C1-1AB5663D69CCQ27022413-3D78F38F-6116-4400-A715-AEDD86A18D3CQ28082536-9DE7BD90-B4A1-4EEE-A60D-80AC8F861DC2Q33386193-FAF76AC7-74B1-47B9-8E46-4652B51A6C1AQ33844751-674FADB9-3FFC-433D-BCE4-72F6BD1FF1A4Q34488424-C0E844DF-865B-4E6D-89E8-CBA88DEB098EQ34503961-0D27FC74-38E2-461C-B93C-663DAF37FD4AQ35006665-FF84A2CE-07EB-4CFA-9C94-751EB659FE43Q36616790-9B5554A4-1DD5-492C-8CC2-AFC30965B1D3Q37536821-7CF3D5D1-3536-4F70-B714-D6DD026B48DDQ37621256-1BB14B2E-D044-408B-BCB5-0D81EC179251Q37774667-A95057EA-A765-4240-B7D0-4BE60ECE7F72Q37873498-09DCB6E5-77F0-48AB-B6CA-3DCB606F73B3Q38071321-01EA82DE-CB73-4B60-B099-979B1566E9A2Q38090679-FB9C91A7-B779-432B-97AC-91269725E127Q38595978-492562C2-8F54-4A1B-A063-1A09EF3F0E10Q38716684-74D2D487-E874-45A8-AD11-0B8D7DC789CFQ38974433-D67ED029-12A5-45A4-B912-BFDF50937398Q39023986-79DD8B31-739B-4A96-9C23-C1B32C6358D9Q39062353-4C270601-BD98-4B4D-96E9-7110A1ED8532Q39066800-2586A1ED-4E95-40A5-AF37-70C12A27CE9DQ39077976-734A9701-89AA-44AC-8B52-78F8ADAAAEF6Q39581269-BCE59C0F-051B-4545-A4D1-1C178DC352FFQ39785574-9A52DF59-F7E7-496D-BEC6-D4F9E3620A2AQ41347312-940AF899-D4A3-4D2D-892D-EA53DC690223Q41664067-C0A5DAA2-B841-4701-8794-06D0AC9E487EQ42109512-4F997102-7D40-483A-8124-C9666B814B47Q42368154-DC7A8807-C104-49B4-B2D8-A027BEF86FF9Q42721017-BDE299A2-7B5E-4610-9BC4-D3D0DCA0326DQ43034405-091C17C3-EEBE-46D1-A7B5-D774D317ECC0Q43092116-41909A0A-DA9A-4C6B-AFC5-0F0A90397872Q49853764-05129B9D-F12C-4D39-AF75-C85CE956CA1AQ51755936-5FA01559-B51C-4A02-B13D-0B7DA87C592EQ52097904-C3AAE9F2-D60A-4C43-91CF-D2052F3E8042
P2860
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@ast
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@en
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@nl
type
label
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@ast
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@en
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@nl
prefLabel
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@ast
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@en
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@nl
P2093
P2860
P1476
Evaluation of the pharmacodyna ...... ing a novel HDAC enzyme assay.
@en
P2093
Ann Kalita
Claire Bonfils
Gregory Reid
Jeffrey M Besterman
Lillian L Siu
Marja Dubay
Michael A Carducci
Robert E Martell
P2860
P304
P356
10.1158/1078-0432.CCR-07-4427
P407
P577
2008-06-01T00:00:00Z